Recently published research papers and articles http://www.epda.eu.com/research-news.rss The perioperative adverse events in this trial of subjects with early stage PD are comparable with those reported for STN-DBS in advanced PD. The active contact position used in early PD is not significantly different from that used in late stage disease. http://www.epda.eu.com/research-papers/2012/jnnp/2012-02-01-jnnp/ 14806 Wed, 01 Feb 2012 00:00:00 GMT 20120201000000 Mon, 19 Sep 2011 08:52:26 GMT 20110919085226 Mon, 30 Jan 2012 13:25:40 GMT 201201301312540 Marked grey matter atrophy occurs in PD with dementia but far less extensive changes are evident in PD-MCI. Some grey matter atrophy precedes the development of dementia but may be accelerated once frank dementia begins. http://www.epda.eu.com/research-papers/2012/jnnp/2012-02-01-jnnp-1/ 14805 Wed, 01 Feb 2012 00:00:00 GMT 20120201000000 Mon, 19 Sep 2011 08:44:19 GMT 20110919084419 Mon, 30 Jan 2012 13:26:27 GMT 201201301312627 Interpretation: Constant-current DBS of the subthalamic nucleus produced significant improvements in good quality on time when compared with a control group without stimulation. Future trials should compare the effects of constant-current DBS with those of voltage-controlled stimulation. http://www.epda.eu.com/research-papers/2012/lancet-neurology/2012-02-01-lancet/ 16421 Wed, 01 Feb 2012 00:00:00 GMT 20120201000000 Mon, 30 Jan 2012 15:07:51 GMT 20120130150751 Wed, 01 Feb 2012 14:32:08 GMT 201202011423208 PD patients were aware of problems with executive functions in daily life and reported considerably more problems than healthy controls. These problems were however not reflected by neuropsychological tests and may indicate a lack of ecological validity of neuropsychological assessment. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-02-01-prelatdisord-2/ 15276 Wed, 01 Feb 2012 00:00:00 GMT 20120201000000 Wed, 02 Nov 2011 14:17:47 GMT 20111102141747 Thu, 02 Feb 2012 10:31:02 GMT 2012020210103102 Conclusions: Patients with PD have a decreased sense of humor compared to healthy controls. Utilizing audio methods of presentation and humor in an obvious mode appears to be the preferred approach for eliciting responses to humor in a PD population. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-02-01-prelatdisord-3/ 15272 Wed, 01 Feb 2012 00:00:00 GMT 20120201000000 Wed, 02 Nov 2011 13:39:26 GMT 20111102133926 Thu, 02 Feb 2012 16:28:58 GMT 201202021642858 This study identified regulator of G protein signaling 4 (RGS4) as a key link between D2/A2A signaling and eCB mobilization pathways. In contrast to wild-type mice, RGS4/ mice exhibited normal eCB-LTD after dopamine depletion and were significantly less impaired in the 6-OHDA model of Parkinson's disease. Taken together, these results suggest that inhibition of RGS4 may be an effective nondopaminergic strategy for treating Parkinson's disease. http://www.epda.eu.com/research-papers/2012/2012-01-26-neuron/ 16414 Thu, 26 Jan 2012 00:00:00 GMT 20120126000000 Mon, 30 Jan 2012 13:29:09 GMT 20120130132909 Mon, 30 Jan 2012 14:46:03 GMT 201201301424603 Vitamin B12 supplementation may need to be considered in PD patients on duodenal levodopa infusion therapy. Vitamin B12 deficiency in patients on duodenal levodopa infusion therapy may be more frequent than the published data suggest. We must be alert. http://www.epda.eu.com/research-papers/2012/journal-of-neurology/2012-01-24-jneurol/ 16486 Tue, 24 Jan 2012 00:00:00 GMT 20120124000000 Wed, 01 Feb 2012 14:24:22 GMT 20120201142422 Wed, 01 Feb 2012 14:31:00 GMT 201202011423100 In PD, switch time and movement velocity of the lower limb, but not the eyes, correlated with bradykinesia and postural instability/gait. Study results suggest that individuals with PD experience movement-switching deficits with both the eyes and lower limb, perhaps driven by overall bradykinesia. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-01-18-prelatdisord/ 16413 Wed, 18 Jan 2012 00:00:00 GMT 20120118000000 Mon, 30 Jan 2012 13:18:29 GMT 20120130131829 Mon, 30 Jan 2012 15:03:10 GMT 201201301530310 Exploratory analysis of the primary endpoint for 100 mg/day demonstrated that the addition of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation. http://www.epda.eu.com/research-papers/2012/movement-disorders-journal/2012-01-15-movdisord/ 14909 Sun, 15 Jan 2012 00:00:00 GMT 20120115000000 Mon, 03 Oct 2011 10:28:14 GMT 20111003102814 Mon, 30 Jan 2012 07:47:08 GMT 201201300774708 The results demonstrate that both affective and cognitive aspects of theory of mind are simultaneously impaired in early PD and suggest that deficits in the 2 subcomponents of theory of mind may be linked to dysfunction of different frontosubcortical circuitries in early PD. http://www.epda.eu.com/research-papers/2012/movement-disorders-journal/2012-01-15-movdisord-1/ 14866 Sun, 15 Jan 2012 00:00:00 GMT 20120115000000 Mon, 26 Sep 2011 17:12:47 GMT 20110926171247 Mon, 30 Jan 2012 08:37:49 GMT 201201300883749 The present imaging study suggests that abnormalities in serotonin 1A receptor neurotransmission in the limbic system may be involved in the neural mechanisms underlying depression in patients with Parkinson's disease. http://www.epda.eu.com/research-papers/2012/movement-disorders-journal/2012-01-12-movdisord-2/ 15205 Sun, 15 Jan 2012 00:00:00 GMT 20120115000000 Wed, 26 Oct 2011 16:16:31 GMT 20111026161631 Mon, 30 Jan 2012 08:40:28 GMT 201201300884028 Despite the major roles of NE throughout the brain, there has been only minimal exploration of pharmacological intervention with NErgic neurotransmission.... This article reviews the reported pharmacological experience in PD therapeutics. http://www.epda.eu.com/research-papers/2012/2012-01-13-transneurodegen/ 16282 Fri, 13 Jan 2012 00:00:00 GMT 20120113000000 Wed, 18 Jan 2012 12:07:47 GMT 20120118120747 Mon, 30 Jan 2012 08:44:52 GMT 201201300884452 The authors propose that this technology offers a robust and cost-effective alternative to targeted sequencing using traditional sequencing methods, and here we demonstrate the potential of this approach for either routine clinical investigation or for research studies aimed at understanding the genetic aetiology of PD. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-01-12-prelatdisord-1/ 16418 Thu, 12 Jan 2012 00:00:00 GMT 20120112000000 Mon, 30 Jan 2012 14:56:46 GMT 20120130145646 Mon, 30 Jan 2012 15:32:57 GMT 201201301533257 Conclusions: True on FOG exists as a rare phenotype in PD, unassociated with cognitive impairment or a predating off FOG. Distinguishing the different FOG subtypes requires a comprehensive motor assessment in at least 3 medication states. http://www.epda.eu.com/research-papers/2012/neurology/2012-01-18-neurology/ 16417 Thu, 12 Jan 2012 00:00:00 GMT 20120112000000 Mon, 30 Jan 2012 14:50:45 GMT 20120130145045 Mon, 30 Jan 2012 14:54:53 GMT 201201301425453 Q10 items were selected from the QUICK validation study data set through statistical analysis and it was then tested on a sample of 162 PD patients, 64.8% with wearing-off. Sensitivity, specificity, and accuracy were 96%, 63%, and 85% respectively with one positive response and 90%, 70%, and 83% respectively with two positive responses. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-01-12-prelatdisord/ 16412 Thu, 12 Jan 2012 00:00:00 GMT 20120112000000 Mon, 30 Jan 2012 13:10:53 GMT 20120130131053 Mon, 30 Jan 2012 13:17:09 GMT 201201301311709 To conclude, in this study significant differences between men and women in prevalence and severity of fatigue, mood, sexual and digestive problems, pain, restless legs, and daytime sleepiness were found. Gender-related patterns of NMS involvement may be relevant for clinical trials in PD. http://www.epda.eu.com/research-papers/2012/journal-of-neurology/2012-01-12-jneurol/ 16331 Thu, 12 Jan 2012 00:00:00 GMT 20120112000000 Mon, 23 Jan 2012 15:31:55 GMT 20120123153155 Mon, 23 Jan 2012 15:48:46 GMT 201201231534846 Exploratory analysis of the primary endpoint for 100 mg/day demonstrated that the addition of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation. http://www.epda.eu.com/research-papers/2012/movement-disorders-journal/2012-01-11-movdisord/ 16329 Wed, 11 Jan 2012 00:00:00 GMT 20120111000000 Mon, 23 Jan 2012 15:22:31 GMT 20120123152231 Mon, 23 Jan 2012 15:27:51 GMT 201201231532751 Study data suggest that the PRKN gene mutation is the most frequent form of ARPD in Turkey. The proportion of mutations with regard to the age of onset in our population is in the range of those previously described, but our pedigrees are characterized by high rate of consanguinity, which might explain the high proportion of families with homozygous mutations and of patients in more than one generation. http://www.epda.eu.com/research-papers/2012/european-journal-of-neurology/2012-01-10-eurjneurol/ 16326 Tue, 10 Jan 2012 00:00:00 GMT 20120110000000 Mon, 23 Jan 2012 14:52:05 GMT 20120123145205 Mon, 23 Jan 2012 14:58:24 GMT 201201231425824 Conclusion: Adherence to regular PD medication dosing schedules during hospitalization is problematic, but improves with specialist consultation. Staff involved in the admission process for PD patients should work to safeguard against disruption of the prescribed home dosing schedule. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-01-09-prelatdisord/ 16327 Mon, 09 Jan 2012 00:00:00 GMT 20120109000000 Mon, 23 Jan 2012 15:09:03 GMT 20120123150903 Mon, 23 Jan 2012 15:20:44 GMT 201201231532044 Surprisingly, only 52.4% of PD patients with pain used analgesics, most often nonopioids. PD patients seem to be predisposed to develop pain and physicians should be aware of pain as a common feature of PD. http://www.epda.eu.com/research-papers/2012/movement-disorders-journal/2012-01-09-movdisord/ 16325 Mon, 09 Jan 2012 00:00:00 GMT 20120109000000 Mon, 23 Jan 2012 14:45:14 GMT 20120123144514 Mon, 23 Jan 2012 14:49:45 GMT 201201231424945 The authors therefore propose that mitochondrial dysfunction in parkin mutants induces Parkinsonian bradykinesia via a neuronal energy deficit and resulting synaptic failure, rather than as a consequence of downstream oxidative stress. http://www.epda.eu.com/research-papers/2012/2012-01-03-hummolgenet/ 16283 Tue, 03 Jan 2012 00:00:00 GMT 20120103000000 Wed, 18 Jan 2012 12:30:18 GMT 20120118123018 Mon, 30 Jan 2012 08:47:49 GMT 201201300884749 In conclusion, the present study reveals that mutations in the parkin gene are not a major contributor to PD in the South African population. Further investigations of the molecular etiology of PD in the unique South African population, particularly the Black African and mixed ancestry sub-populations, are warranted. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-02-01-prelatdisord-16/ 15273 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Wed, 02 Nov 2011 13:45:44 GMT 20111102134544 Fri, 03 Feb 2012 20:52:11 GMT 201202032085211 This study investigated economy of gait during submaximal treadmill walking in 79 subjects with mild to moderate PD and the relationship between gait economy and 6-minute walk distance (6 MW). http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd/ 16333 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Mon, 23 Jan 2012 15:59:07 GMT 20120123155907 Mon, 23 Jan 2012 16:09:41 GMT 201201231640941 These results have implications for rehabilitation clinicians and suggest that walking ability is the primary target in order to reduce FOF. Specifically, balance, climbing stairs, and turning seem to be of particular importance. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-1/ 16336 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Mon, 23 Jan 2012 16:10:47 GMT 20120123161047 Mon, 23 Jan 2012 16:14:11 GMT 201201231641411 This is the first study to demonstrate that the UPDRS-PG score and knee muscle strength are important and independent determinants of the level of fear of falling in individuals with PD. Improving balance, gait stability and knee muscle strength could be crucial in promoting balance confidence in the appropriately targeted PD population. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-3/ 16338 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Mon, 23 Jan 2012 16:34:01 GMT 20120123163401 Mon, 23 Jan 2012 16:40:40 GMT 201201231644040 The review will consider the biochemical evidence indicating that the serotonergic neurons are involved in the dopaminergic effects of L-DOPA in the brain. The consequences are an ectopic and aberrant release of dopamine that follows the serotonergic innervation of the brain. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-4/ 16339 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Mon, 23 Jan 2012 16:41:16 GMT 20120123164116 Mon, 23 Jan 2012 16:45:07 GMT 201201231644507 Since gait improvements were found in both training groups, we conclude that by reducing optic flow, gait benefits associated with visual cueing training can still be achieved. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-2/ 16337 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Mon, 23 Jan 2012 16:29:53 GMT 20120123162953 Wed, 25 Jan 2012 13:12:17 GMT 201201251311217 Preliminary results suggest that the motor improvement often observed in patients with PD following bilateral STN-DBS may be partially offset by an increase in affective-cognitive symptoms of depression. http://www.epda.eu.com/research-papers/2012/european-journal-of-neurology/2012-01-01-eurjneurol/ 13903 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Wed, 29 Jun 2011 14:57:58 GMT 20110629145758 Sun, 29 Jan 2012 20:47:12 GMT 201201292084712 Disability and quality of life assessment tools measure psychosocial facets that are similar specifically with regard to physical health component of health-related quality of life, are sensitive enough to capture differences related to disease's progression and increased prevalence of NMS. http://www.epda.eu.com/research-papers/2012/parkinsonism-related-disorders/2012-01-01-prelatdisord-15/ 14803 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Fri, 16 Sep 2011 15:59:02 GMT 20110916155902 Mon, 30 Jan 2012 07:39:36 GMT 201201300773936 Significantly differences between testing sessions were identified for knee extension (P 0.90) was also identified between sessions. Interestingly, almost third of subjects failed to perform better on the second testing session. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-5/ 16346 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 12:08:38 GMT 20120124120838 Tue, 24 Jan 2012 12:14:31 GMT 2012012412121431 No improvements in gait or turning occurred after five days of rotating treadmill training, compared to one day. The rotating treadmill is not recommended for short-term rehabilitation of impaired in-place turning in the general PD population. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-6/ 16347 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 12:15:17 GMT 20120124121517 Tue, 24 Jan 2012 12:27:23 GMT 2012012412122723 These results support the findings that the practice of upper extremity reaching tasks is beneficial in reducing movement time in persons with PD and has important implications for rehabilitation. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-7/ 16348 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 12:28:57 GMT 20120124122857 Tue, 24 Jan 2012 12:51:36 GMT 2012012412125136 This study evaluated the feasibility of rehabilitation programs within the context of a large randomized controlled trial of physical therapy. Ambulant participants with Parkinson's disease (PD) (n = 210) were randomized into three groups. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-8/ 16349 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 12:54:31 GMT 20120124125431 Tue, 24 Jan 2012 13:00:01 GMT 201201241310001 The most promising neuroprotective investigative priorities will involve disease-modifying trials of the safest agents alone or in combination to capture salutary effects on H3 histone deacetylase, gene transcription, glycogen synthase kinase-3, α-synuclein, reactive oxygen species (ROS), reactive nitrogen species (RNS), apoptosis, inflammation, and trophic factors including GDNF and BDNF. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-9/ 16350 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 13:01:35 GMT 20120124130135 Tue, 24 Jan 2012 13:04:41 GMT 201201241310441 The proposed theoretical framework sets the stage for testable hypotheses regarding the mechanisms that lead to FOG and may also lead to new treatment ideas. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-10/ 16351 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 13:07:54 GMT 20120124130754 Tue, 24 Jan 2012 13:11:02 GMT 201201241311102 The risk of falls increased exponentially with age, especially from 70 years onward. Patients aged >70 years at the onset of Parkinson's disease experienced falls significantly earlier than younger patients. http://www.epda.eu.com/research-papers/2012/parkinsons-disease/2012-01-01-pd-11/ 16352 Sun, 01 Jan 2012 00:00:00 GMT 20120101000000 Tue, 24 Jan 2012 13:12:03 GMT 20120124131203 Tue, 24 Jan 2012 13:14:22 GMT 201201241311422 This study identified new components of the proteostasis network that can suppress aggregation and proteotoxicity, by performing RNA interference (RNAi) genetic screens for multiple unrelated conformationally challenged cytoplasmic proteins expressed in Caenorhabditis elegans. http://www.epda.eu.com/research-papers/2011/2011-12-29-plosgen/ 16344 Thu, 29 Dec 2011 00:00:00 GMT 20111229000000 Tue, 24 Jan 2012 11:46:08 GMT 20120124114608 Tue, 24 Jan 2012 11:54:54 GMT 2012012411115454 In vivo survival and function is demonstrated in Parkinson's disease models using three host species. Long-term engraftment in 6-hydroxy-dopamine-lesioned mice and rats demonstrates robust survival of midbrain DA neurons derived from human embryonic stem (ES) cells, complete restoration of amphetamine-induced rotation behaviour and improvements in tests of forelimb use and akinesia. http://www.epda.eu.com/research-papers/2011/2011-12-21-nature/ 16424 Wed, 21 Dec 2011 00:00:00 GMT 20111221000000 Mon, 30 Jan 2012 18:46:24 GMT 20120130184624 Mon, 30 Jan 2012 18:57:23 GMT 201201301865723 In this study authors have demonstrated that the administration of a novel noncoding p137 RNA, derived from the human cytomegaloviral β2.7 transcript, can prevent and rescue dopaminergic cell death in vitro and in animal models of PD by protecting mitochondrial Complex I activity. http://www.epda.eu.com/research-papers/2011/2011-12-19-jexpermed/ 16345 Mon, 19 Dec 2011 00:00:00 GMT 20111219000000 Tue, 24 Jan 2012 11:57:27 GMT 20120124115727 Tue, 24 Jan 2012 12:02:01 GMT 2012012412120201 Multivariate analysis showed a significant positive association between use of oral contraceptives and PD, with an adjusted OR of 3.27 (95% CI, 1.248.59; P = .01). http://www.epda.eu.com/research-papers/2011/2011-12-15-movdisord-3/ 15140 Thu, 15 Dec 2011 00:00:00 GMT 20111215000000 Fri, 14 Oct 2011 19:51:00 GMT 20111014195100 Mon, 30 Jan 2012 07:41:50 GMT 201201300774150 This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. http://www.epda.eu.com/research-papers/2011/2011-12-15-movdisord-1/ 16109 Thu, 15 Dec 2011 00:00:00 GMT 20111215000000 Tue, 03 Jan 2012 08:06:14 GMT 20120103080614 Sun, 29 Jan 2012 20:50:35 GMT 201201292085035 Using this approach, the authors identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model. http://www.epda.eu.com/research-papers/2011/2011-12-14-plosone/ 16499 Wed, 14 Dec 2011 00:00:00 GMT 20111214000000 Fri, 03 Feb 2012 17:07:22 GMT 20120203170722 Fri, 03 Feb 2012 17:18:31 GMT 201202031751831 Conclusion:  In this casecontrol study in Japan, a dietary pattern consisting of high intakes of vegetables, fruits and fish may be associated with a decreased risk of PD. http://www.epda.eu.com/research-papers/2011/2011-12-05-eurjneurol-1/ 16423 Mon, 05 Dec 2011 00:00:00 GMT 20111205000000 Mon, 30 Jan 2012 17:15:09 GMT 20120130171509 Mon, 30 Jan 2012 17:28:34 GMT 201201301752834 Doctors only provided a small proportion of patients with advanced therapy information, despite patients' interest. Hence, improvement is warranted regarding doctor appointments, information about various advanced treatment options, and their availability. http://www.epda.eu.com/research-papers/2011/2011-12-01-jmdh/ 16353 Thu, 01 Dec 2011 00:00:00 GMT 20111201000000 Tue, 24 Jan 2012 13:35:42 GMT 20120124133542 Tue, 24 Jan 2012 13:42:35 GMT 201201241314235 The various balance tests were effective in predicting falls at six months. All tests were relatively ineffective at 12 months. Conclusion. This pilot study suggests that people with PD should be assessed biannually for fall risk. http://www.epda.eu.com/research-papers/2011/2011-12-01-pd-3/ 16238 Thu, 01 Dec 2011 00:00:00 GMT 20111201000000 Wed, 11 Jan 2012 15:10:34 GMT 20120111151034 Mon, 23 Jan 2012 22:03:40 GMT 2012012322100340 Patients with mild parkinsonian symptoms, excellent response to low dosages of dopaminergic drugs and a reduced dopamine-transporter uptake in [123I] FP-CIT-SPECT might more commonly be GCH1 mutation carriers than has previously been supposed. PD patients with a positive family history of DRD and combination of these clinical symptoms should be offered genetic counselling and testing for GCH1. http://www.epda.eu.com/research-papers/2011/2011-10-24-prelatdisord/ 15325 Mon, 24 Oct 2011 00:00:00 GMT 20111024000000 Mon, 07 Nov 2011 18:48:56 GMT 20111107184856 Thu, 02 Feb 2012 10:37:37 GMT 2012020210103737 This study describes clinical, electromyographic (EMG), and radiological features of PS in a group of 20 PD patients. All patients with trunk deviation underwent EMG and radiological (RX and CT scan) investigation. http://www.epda.eu.com/research-papers/2011/2011-10-13-movdisord/ 15271 Thu, 13 Oct 2011 00:00:00 GMT 20111013000000 Wed, 02 Nov 2011 13:27:13 GMT 20111102132713 Thu, 02 Feb 2012 08:53:58 GMT 201202020885358 The findings demonstrate that dance has beneficial effect on the functional mobility of individuals with PD. Further, dance improves the quality of life of the patients and their caregivers. Dance may lead to better therapeutic strategies as it is engaging and enjoyable. http://www.epda.eu.com/research-papers/2011/2011-10-10-frontagneurosci/ 16340 Mon, 10 Oct 2011 00:00:00 GMT 20111010000000 Tue, 24 Jan 2012 09:21:58 GMT 20120124092158 Tue, 24 Jan 2012 09:28:44 GMT 201201240992844 This study suggests that newly acquired artistic-like production in patients with PD is not associated with impulsivity or ICDs. Artistic-like production might represent the emerging of innate skills in a subset of predisposed patients with PD on dopaminergic therapy. http://www.epda.eu.com/research-papers/2011/2011-10-10-eurjneurol/ 15208 Mon, 10 Oct 2011 00:00:00 GMT 20111010000000 Wed, 26 Oct 2011 17:58:11 GMT 20111026175811 Mon, 23 Jan 2012 14:39:15 GMT 201201231423915 As both tests are easy to perform, noninvasive, and inexpensive, the combination of TCS of the SN and olfactory testing may contribute to early and accurate diagnosis of PD. http://www.epda.eu.com/research-papers/2011/2011-10-07-eurjneurol/ 15210 Fri, 07 Oct 2011 00:00:00 GMT 20111007000000 Wed, 26 Oct 2011 18:12:57 GMT 20111026181257 Mon, 23 Jan 2012 14:38:30 GMT 201201231423830 Higher UPDRS dyskinesia score, UPDRS instability score, UPDRS total score, Hoehn and Yahr stage, and presence of intellectual impairment at baseline were all associated with increased risk of future loss of ability to work and loss of ability to live independently (P 0.0033). Five years after initial visit, for patients 70 years of age with a disease duration 4 years at initial visit, 88% were still able to work and 90% to live independently. http://www.epda.eu.com/research-papers/2011/2011-10-04-prelatdisord/ 15211 Tue, 04 Oct 2011 00:00:00 GMT 20111004000000 Wed, 26 Oct 2011 18:24:16 GMT 20111026182416 Mon, 23 Jan 2012 14:36:47 GMT 201201231423647 The SFT appears to be a useful tool to assess functional fitness in people with PD: it can be carried out in the clinical setting albeit with some minor modifications. However, its validity as an indicator of disease severity remains to be confirmed. http://www.epda.eu.com/research-papers/2011/2011-10-04-prelatdisord-1/ 15212 Tue, 04 Oct 2011 00:00:00 GMT 20111004000000 Wed, 26 Oct 2011 18:57:28 GMT 20111026185728 Mon, 23 Jan 2012 14:40:05 GMT 201201231424005 Conclusions: Camptocormia is uncommon in PD and is associated with disease severity, higher L-dopa dose and higher frequencies of autonomic symptoms. http://www.epda.eu.com/research-papers/2011/2011-09-27-movdisord-4/ 15143 Tue, 27 Sep 2011 00:00:00 GMT 20110927000000 Sat, 15 Oct 2011 11:09:20 GMT 20111015110920 Mon, 30 Jan 2012 08:41:51 GMT 201201300884151 Bladder dysfunction (urinary urgency/frequency), bowel dysfunction (constipation), and sexual dysfunction (erectile dysfunction) (also called pelvic organ dysfunctions) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, pelvic organ autonomic dysfunctions are often nonresponsive to levodopa treatment. http://www.epda.eu.com/research-papers/2011/2011-09-12-pd/ 16151 Mon, 12 Sep 2011 00:00:00 GMT 20110912000000 Wed, 04 Jan 2012 11:51:12 GMT 20120104115112 Mon, 23 Jan 2012 16:51:18 GMT 201201231645118